PB2038: LENALIDOMIDE OR BORTEZOMIB AS MAINTENANCE TREATMENT OVERCOMES INFERIOR IMPACT OF HIGH-RISK CYTOGENETIC ABNORMALITIES IN TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA IN CHINA

Detalles Bibliográficos
Autores principales: Zhuang, Z., Tian, Y., Shi, L., Zou, D., Feng, R., Tian, W.-W., Yu, H., Dong, F., Liao, A., Ma, Y., Liu, Q., Liu, S., Jing, H., Fu, R., Ma, L.-M., Liu, H., Sun, W., Bao, L., Wu, Y., Chen, W., Zhuang, J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Publication Only
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431666/
http://dx.doi.org/10.1097/01.HS9.0000850984.40192.e8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431666/
http://dx.doi.org/10.1097/01.HS9.0000850984.40192.e8

Ejemplares similares